INTRODUCTION: Balloon angioplasty can be a requisite approach for the treatment of symptomatic and/or severe vasospasm. Dual-lumen microcatheter balloons have multiple potential advantages for this indication including accommodating a 0.014-inch wire and the potential to deliver superselective vasodilators directly via the microcatheter prior to angioplasty. METHODS: The authors reviewed a 3-year institutional experience with the Scepter XC balloon (Microvention, Tustin, CA, USA) in the treatment of postaneurysmal subarachnoid hemorrhage vasospasm, focusing on treatment methods, angiographic, and clinical results. RESULTS: Sixty-four vessels were treated in 18 patients. Fifteen cases were performed under intravenous (i.v.) conscious sedation (83%). The mean pretreatment stenosis was 59% (range 40-80), and the mean post-treatment stenosis was 12% (range 0-40). Five vessels in 3 patients were subsequently retreated via angioplasty for recurrent vasospasm (8%). There were no complications related to the passage of the balloon microcatheter or inflation of the balloon such as dissection or vessel rupture. Of 14 patients with delayed cerebral ischemia, 7 had complete symptomatic resolution after treatment, and 3 had significant symptomatic improvement. Four patients did not improve after treatment though 3 already had confirmed infarcts on imaging prior to angiography. CONCLUSION: The Scepter XC is a safe and effective balloon microcatheter for angioplasty of cerebral vasospasm after subarachnoid hemorrhage, allowing for superselective delivery of a vasodilator. Its ease of deliverability and visibility often allows for the performance of the procedure under i.v. conscious sedation.
INTRODUCTION: Balloon angioplasty can be a requisite approach for the treatment of symptomatic and/or severe vasospasm. Dual-lumen microcatheter balloons have multiple potential advantages for this indication including accommodating a 0.014-inch wire and the potential to deliver superselective vasodilators directly via the microcatheter prior to angioplasty. METHODS: The authors reviewed a 3-year institutional experience with the Scepter XC balloon (Microvention, Tustin, CA, USA) in the treatment of postaneurysmal subarachnoid hemorrhage vasospasm, focusing on treatment methods, angiographic, and clinical results. RESULTS: Sixty-four vessels were treated in 18 patients. Fifteen cases were performed under intravenous (i.v.) conscious sedation (83%). The mean pretreatment stenosis was 59% (range 40-80), and the mean post-treatment stenosis was 12% (range 0-40). Five vessels in 3 patients were subsequently retreated via angioplasty for recurrent vasospasm (8%). There were no complications related to the passage of the balloon microcatheter or inflation of the balloon such as dissection or vessel rupture. Of 14 patients with delayed cerebral ischemia, 7 had complete symptomatic resolution after treatment, and 3 had significant symptomatic improvement. Four patients did not improve after treatment though 3 already had confirmed infarcts on imaging prior to angiography. CONCLUSION: The Scepter XC is a safe and effective balloon microcatheter for angioplasty of cerebral vasospasm after subarachnoid hemorrhage, allowing for superselective delivery of a vasodilator. Its ease of deliverability and visibility often allows for the performance of the procedure under i.v. conscious sedation.
Authors: Alejandro M Spiotta; Robert F James; Stephen R Lowe; Jan Vargas; Aquilla S Turk; M Imran Chaudry; Tarun Bhalla; Rashid M Janjua; John J Delaney; Stacey Quintero-Wolfe; Raymond D Turner Journal: J Neurointerv Surg Date: 2014-08-12 Impact factor: 5.836
Authors: Apar S Patel; Christoph J Griessenauer; Raghav Gupta; Nimer Adeeb; Paul M Foreman; Hussain Shallwani; Justin M Moore; Mark R Harrigan; Adnan H Siddiqui; Christopher S Ogilvy; Ajith J Thomas Journal: World Neurosurg Date: 2016-10-21 Impact factor: 2.104
Authors: Bharathi D Jagadeesan; Mikayel Grigoryan; Ameer E Hassan; Andrew W Grande; Ramachandra P Tummala Journal: Neurosurgery Date: 2013-12 Impact factor: 4.654
Authors: E Sander Connolly; Alejandro A Rabinstein; J Ricardo Carhuapoma; Colin P Derdeyn; Jacques Dion; Randall T Higashida; Brian L Hoh; Catherine J Kirkness; Andrew M Naidech; Christopher S Ogilvy; Aman B Patel; B Gregory Thompson; Paul Vespa Journal: Stroke Date: 2012-05-03 Impact factor: 7.914
Authors: J M Eskridge; W McAuliffe; J K Song; A V Deliganis; D W Newell; D H Lewis; M R Mayberg; H R Winn Journal: Neurosurgery Date: 1998-03 Impact factor: 4.654
Authors: Neeraj Badjatia; Mehmet A Topcuoglu; Johnny C Pryor; James D Rabinov; Christopher S Ogilvy; Bob S Carter; Guy A Rordorf Journal: AJNR Am J Neuroradiol Date: 2004-05 Impact factor: 3.825
Authors: Seby John; Alejandro M Spiotta; Raymond M Turner; M Imran Chaudry; Aquilla S Turk; Ferdinand Hui Journal: J Neurointerv Surg Date: 2013-01-31 Impact factor: 5.836
Authors: Alexander Neumann; Jan Küchler; Claudia Ditz; Kara Krajewski; Jan Leppert; Peter Schramm; Hannes Schacht Journal: Stroke Vasc Neurol Date: 2020-07-23